NF1 is altered in 7.15% of malignant solid tumor patients with NF1 Loss present in 0.37% of all malignant solid tumor patients [4].

NF1 Loss is an inclusion criterion in 26 clinical trials for malignant solid tumor, of which 23 are open and 3 are closed. Of the trials that contain NF1 Loss and malignant solid tumor as inclusion criteria, 13 are phase 1 (11 open), 4 are phase 1/phase 2 (4 open), and 9 are phase 2 (8 open) [5].

NF1 is altered in 8.52% of non-small cell lung carcinoma patients with NF1 Loss present in 0.06% of all non-small cell lung carcinoma patients [4].

NF1 Loss is an inclusion criterion in 13 clinical trials for non-small cell lung carcinoma, of which 10 are open and 3 are closed. Of the trials that contain NF1 Loss and non-small cell lung carcinoma as inclusion criteria, 8 are phase 1 (7 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (1 open) [5].

NF1 is altered in 24.25% of melanoma patients with NF1 Loss present in 1.29% of all melanoma patients [4].

NF1 Loss is an inclusion criterion in 6 clinical trials for melanoma, of which 5 are open and 1 is closed. Of the trials that contain NF1 Loss and melanoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

NF1 Loss is an inclusion criterion in 6 clinical trials for neurofibromatosis type 1, of which 5 are open and 1 is closed. Of the trials that contain NF1 Loss and neurofibromatosis type 1 as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 5 are phase 2 (4 open) [5].

NF1 is altered in 14.96% of glioma patients with NF1 Loss present in 0.45% of all glioma patients [4].

NF1 Loss is an inclusion criterion in 5 clinical trials for glioma, of which 3 are open and 2 are closed. Of the trials that contain NF1 Loss and glioma as inclusion criteria, 4 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [5].

NF1 is altered in 8.15% of low grade glioma patients with NF1 Loss present in 0.3% of all low grade glioma patients [4].

NF1 Loss is an inclusion criterion in 5 clinical trials for low grade glioma, of which 5 are open and 0 are closed. Of the trials that contain NF1 Loss and low grade glioma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [5].

NF1 is altered in 56.25% of neurofibroma patients [4].

NF1 Loss is an inclusion criterion in 5 clinical trials for neurofibroma, of which 2 are open and 3 are closed. Of the trials that contain NF1 Loss and neurofibroma as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [5].

NF1 is altered in 34.78% of malignant peripheral nerve sheath tumor patients with NF1 Loss present in 6.02% of all malignant peripheral nerve sheath tumor patients [4].

NF1 Loss is an inclusion criterion in 4 clinical trials for malignant peripheral nerve sheath tumor, of which 1 is open and 3 are closed. Of the trials that contain NF1 Loss and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].

NF1 Loss is an inclusion criterion in 4 clinical trials for plexiform neurofibroma, of which 4 are open and 0 are closed. Of the trials that contain NF1 Loss and plexiform neurofibroma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].

NF1 is altered in 8.01% of ovarian carcinoma patients with NF1 Loss present in 2.09% of all ovarian carcinoma patients [4].

NF1 Loss is an inclusion criterion in 3 clinical trials for ovarian carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NF1 Loss and ovarian carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 3.95% of acute myeloid leukemia patients with NF1 Loss present in 0.19% of all acute myeloid leukemia patients [4].

NF1 Loss is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain NF1 Loss and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

NF1 is altered in 5.51% of colorectal carcinoma patients with NF1 Loss present in 0.14% of all colorectal carcinoma patients [4].

NF1 Loss is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NF1 Loss and colorectal carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 4.3% of chronic myelomonocytic leukemia patients [4].

NF1 Loss is an inclusion criterion in 3 clinical trials for chronic myelomonocytic leukemia, of which 3 are open and 0 are closed. Of the trials that contain NF1 Loss and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

NF1 is altered in 1.6% of myelodysplastic syndromes patients [4].

NF1 Loss is an inclusion criterion in 3 clinical trials for myelodysplastic syndromes, of which 3 are open and 0 are closed. Of the trials that contain NF1 Loss and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

NF1 is altered in 1.77% of non-hodgkin lymphoma patients [4].

NF1 Loss is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain NF1 Loss and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [5].

NF1 is altered in 5.88% of breast carcinoma patients with NF1 Loss present in 0.48% of all breast carcinoma patients [4].

NF1 Loss is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NF1 Loss and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 1.78% of pancreatic carcinoma patients with NF1 Loss present in 0.08% of all pancreatic carcinoma patients [4].

NF1 Loss is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NF1 Loss and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 2.33% of histiocytic and dendritic cell neoplasm patients [4].

NF1 Loss is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain NF1 Loss and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [5].

NF1 is altered in 0.47% of multiple myeloma patients [4].

NF1 Loss is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain NF1 Loss and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

NF1 Loss is an inclusion criterion in 2 clinical trials for optic nerve glioma, of which 2 are open and 0 are closed. Of the trials that contain NF1 Loss and optic nerve glioma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

NF1 is altered in 9.2% of pilocytic astrocytoma patients [4].

NF1 Loss is an inclusion criterion in 2 clinical trials for pilocytic astrocytoma, of which 2 are open and 0 are closed. Of the trials that contain NF1 Loss and pilocytic astrocytoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

NF1 is altered in 3.97% of thyroid gland carcinoma patients [4].

NF1 Loss is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NF1 Loss and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

NF1 is altered in 29.38% of mucosal melanoma patients with NF1 Loss present in 13.7% of all mucosal melanoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NF1 is altered in 14.67% of embryonal rhabdomyosarcoma patients with NF1 Loss present in 4.55% of all embryonal rhabdomyosarcoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 8.26% of malignant female reproductive system neoplasm patients with NF1 Loss present in 1.18% of all malignant female reproductive system neoplasm patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for malignant female reproductive system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and malignant female reproductive system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

NF1 is altered in 5.89% of sarcoma patients with NF1 Loss present in 1.15% of all sarcoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NF1 Loss and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF1 is altered in 5.66% of soft tissue sarcoma patients with NF1 Loss present in 1.08% of all soft tissue sarcoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 4.9% of gastrointestinal stromal tumor patients with NF1 Loss present in 1.03% of all gastrointestinal stromal tumor patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 0 are open and 1 is closed. Of the trial that contains NF1 Loss and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

NF1 is altered in 19.32% of glioblastoma patients with NF1 Loss present in 0.57% of all glioblastoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains NF1 Loss and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF1 is altered in 17.4% of malignant glioma patients with NF1 Loss present in 0.51% of all malignant glioma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and malignant glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 16.97% of astrocytic tumor patients with NF1 Loss present in 0.46% of all astrocytic tumor patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 16.09% of diffuse glioma patients with NF1 Loss present in 0.4% of all diffuse glioma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 7.01% of solid neoplasm patients with NF1 Loss present in 0.36% of all solid neoplasm patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for solid neoplasm, of which 0 are open and 1 is closed. Of the trial that contains NF1 Loss and solid neoplasm as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

NF1 is altered in 6.84% of cancer patients with NF1 Loss present in 0.35% of all cancer patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains NF1 Loss and cancer as inclusion criteria, 1 is early phase 1 (0 open) [5].

NF1 is altered in 10.67% of endometrial carcinoma patients with NF1 Loss present in 0.34% of all endometrial carcinoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 2.97% of neuroblastoma patients with NF1 Loss present in 0.29% of all neuroblastoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 4.2% of head and neck carcinoma patients with NF1 Loss present in 0.19% of all head and neck carcinoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF1 Loss and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF1 is altered in 2.07% of lymphoma patients with NF1 Loss present in 0.16% of all lymphoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains NF1 Loss and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF1 is altered in 2.79% of renal cell carcinoma patients with NF1 Loss present in 0.08% of all renal cell carcinoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 Loss is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].

NF1 is altered in 12.53% of anaplastic astrocytoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains NF1 Loss and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF1 is altered in 1.65% of B-cell non-hodgkin lymphoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NF1 is altered in 8.06% of bladder carcinoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF1 Loss and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF1 is altered in 24.72% of cutaneous melanoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NF1 is altered in 13.33% of dysembryoplastic neuroepithelial tumor patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 Loss is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 6.9% of ganglioglioma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 3.49% of hepatocellular carcinoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NF1 Loss is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

NF1 Loss is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 2.7% of malignant brain neoplasm patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for malignant brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and malignant brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

NF1 Loss is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [5].

NF1 Loss is an inclusion criterion in 1 clinical trial for neurofibromatosis, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and neurofibromatosis as inclusion criteria, 1 is phase 3 (1 open) [5].

NF1 Loss is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1 with plexiform neurofibromas, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and neurofibromatosis type 1 with plexiform neurofibromas as inclusion criteria, 1 is phase 2 (1 open) [5].

NF1 is altered in 6.59% of neuronal and mixed neuronal-glial tumors patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 13.33% of pilomyxoid astrocytoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 5.1% of poorly differentiated thyroid gland carcinoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NF1 is altered in 3.45% of rhabdoid tumor patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 1.49% of schwannoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 7.69% of secondary acute myeloid leukemia patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

NF1 is altered in 9.57% of squamous cell lung carcinoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF1 is altered in 7.69% of therapy-related acute myeloid leukemia patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

NF1 Loss is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].

NF1 is altered in 11.81% of thyroid gland undifferentiated (anaplastic) carcinoma patients [4].

NF1 Loss is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Loss and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].